Portfolio

Adlore is a medical device company designing the next generation device for the treatment of lower extremity diffucult to heal wounds, i.e. diabetic/neuropathic foot ulcers, venous stasis leg wounds, arterial and ischemic ulcers.

AlertWatch is a healthcare IT company producing clinical decision support systems for hospitals. These systems simplify patient monitoring with intuitive products for the OR and ICU.

Asalyxa Bio is focused on the development of an immune cell targeting platform to create first-in-class particle drug products for diseases with continuing high unmet medical needs.

AureoGen Biosciences is a drug discovery company utilizing state-of-the-art chemistry and genetic engineering methodologies to generate novel drug candidates from existing cyclic peptide templates, focusing on novel antifungal agents.

Tech-enabled healthcare services business that combines state of the art clinical microbiology processes and equipment with specialized sampling techniques to reduce healthcare-associated infections through subscription-based sampling, testing, and germ risk assessments.

Epsilon Imaging is a healthcare IT company transforming cardiac diagnostic workflow with a vendor neutral suite of software applications designed for echocardiography.

Espervita is developing metabolic reprogramming therapies for common forms of cancer, starting with Hepatocellular Carcinomoa as its first indications. The company is using a noval inhibitor for ATP-citrate Lyase.

EVOQ is developing therapeutic High-Density Lipoprotein (HHDL) nanodiscs which are capable of inducing immunological tolerization in patients as a means of treating autoimmune disorders and cancer.

Fifth Eye is developing software to warn medical professionals that certain patients who seem to be doing well after an operation are actually, based on almost imperceptible changes in their vital signs, at risk for serious deterioration in their conditions.

GreenMark is a minimally invasive healthcare company, developing technologies that involve biopolymer nanoparticles produced from natural starch as a raw material.  Given that starch is degraded by natural enzymes in our body, starch nanoparticles are an ideal carrier for dental and medical applications.

Happe Spine is a medical device company focused on developing next generation orthopedic implants with a focus on modifying PEEK technology as fully porous and bioactive, which promotes bone ongrowth and bone ingrowth.

Iaso Therapeutics is dedicated to developing next generation vaccines to enhance human health and treat diseases. Iaso’s initial product offering is a disruptive new virus-like particle, mutant Qβ, that shows superiority in generating antibodies of interest.

INHERET is a digital health company empowering individuals to identify, understand, and manage their risks of hereditary conditions. It will identify individual risk to help personalize screening and therapy programs.

Intervention Insights (acquired by NeoGenomics) is a medical information services company that combines cutting edge bioinformatics tools with disease insight to specify molecularly targeted drugs to help community oncologists develop informed treatment plans for their patients.

M3D is focused on offering devices and services that leverage 3D CZT to the human medical market for real-time radiation imaging.

Magnesium Development Company is a medical device development company delivering a resorbable metal alloy technology for use in surgical screws/plates for application in sports medicine and foot & ankle orthopedics.

MediCool is developing cool cardioversion to painless treat and terminate dangerous cardiac arrhythmias and other disorders.

Native Traits is an agbio company formed to promote the development of its NT RECOVERYTM technology, a propritary technology that enables the company to use ancestral strains of corn, and other grain, as a natural source of genes to improve commercial varieties.

Ocuphire is a biopharmaceuticals company focused on developing and commercializing small molecule drugs for unmet medical needs in the ocular disease space. Ocuphire’s lead drug candidate, Nyxol eye drops, is aimed to treat patients with night vision disturbances (NVD), Glaucoma and Presbyopia (impaired near-term vision).

ONL Therapeutics is a biopharmaceutical company dedicated to the discovery and early clinical development of drugs to treat retinal disorders.

Peptinovo is developing a novel peptide-based delivery platform, Peptide-Amphiphile Lipid Micelle (PALM™), using cancer’s growth pathway to safely carry stronger doses of proven drugs directly into tumors while keeping them away from healthy tissue.

Phrixus Pharmaceuticals is a drug discovery company repurposing an existing drug, Carmeseal-MD, to treat heart failure in boys with Duchenne muscular dystrophy.

Remedy Pharmaceuticals is a drug discovery company repurposing an existing drug, glyburide, to intravenous formulation for the treatment of central nervous system injuries (head injury, stroke).

Reprise Pharmaceuticals is a spin off from Remedy Pharmaceuticals which is developing a drug therapy using the combination of a sulfonylurea drug with another repurposed drug in the treatment of multiple sclerosis (MS), one that could provide an improved treatment option for a subset of multiple sclerosis patients.

RespondWell is a digital health company empowering physical therapists and physicians to engage patients anywhere through telerehabilitation.

SeaStar (fka CytoPherx) Medical is a device company developing therapies to reduce mortality amoung patients with acute kidney failure due to a combination of acute kidney injury, sepsis, and/or multi-organ failure.

Shoulder Innovations is a medical device development company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry, The company’s Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant.

Tetra Therapeutics is a leader in the chemical design of inhibitors of phosphodiesterase (PDE) enzymes.  They are a clinical stage company targeting those suffering from Alzheimer’s disease, traumatic brain injury, and schizophrenia.

Vestaron Corporation has developed and commercialized a new generation of insecticides derived from peptides produced by spiders.

ZuChem is a producer of unique sugars for human consumption. Its primary product is xylitol, based upon carbohydrate chemistry using a scalable manufacturing process.